16
Participants
Start Date
May 13, 2025
Primary Completion Date
May 1, 2026
Study Completion Date
June 30, 2026
Dichloroacetate
Dichloroacetate has a long safety record of administration to humans with a rare metabolic disorder for over 40 years. It has been given orally to patients with T2DM for up to a week without any problems and other laboratory or significant clinical adverse effects were not noted. It activates mitochondrial PDH flux, a key regulator of glucose oxidation.
RECRUITING
Yale-New Haven Hospital, New Haven
Yale University
OTHER